论文部分内容阅读
目的观察孟鲁司特治疗慢性阻塞性肺疾病(COPD)稳定期的临床疗效,探讨孟鲁司特在COPD稳定期中的临床应用价值。方法选取2012年1月~2013年3月在我院内科治疗COPD稳定期患者62例,将其随机分成两组。对照组给予COPD稳定期常规治疗;观察组在COPD稳定期常规平喘、化痰、扩张支气管的基础上加用孟鲁司特口服治疗。根据实验室检查,对比两组患者治疗前、后主要肺功能指标、痰液中各种细胞百分比的改善情况。结果治疗后观察组患者主要肺功能参数、痰液中中性粒细胞及嗜酸性粒细胞百分比改善情况均优于对照组,具有统计学意义(P<0.05)。结论对COPD稳定期患者应用孟鲁司特具有改善肺功能、降低痰液中中性粒细胞及嗜酸性粒细胞百分比的作用,因此孟鲁司特可作为补充性抗炎药物应用于COPD稳定期患者中。
Objective To observe the clinical efficacy of montelukast in the treatment of chronic obstructive pulmonary disease (COPD) in stable period and to explore the clinical value of montelukast in the stable period of COPD. Methods Sixty-two patients with stable COPD in our hospital from January 2012 to March 2013 were randomly divided into two groups. The control group was given routine treatment of stable COPD. The observation group was given montelukast oral treatment on the basis of regular asthma, phlegm and bronchiectasis in stable COPD. According to laboratory tests, the two groups of patients before and after treatment compared the main indicators of lung function, sputum in a variety of cell percentage improvement. Results After treatment, the improvement of main pulmonary function parameters, the percentage of sputum neutrophils and eosinophils in the observation group were better than those in the control group, with statistical significance (P <0.05). Conclusion Montelukast can improve lung function and reduce the percentage of neutrophils and eosinophils in sputum in patients with stable COPD. Therefore, montelukast can be used as a supplementary anti-inflammatory drug in stable stage of COPD In patients.